Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) EBT (2020 - 2025)

Maravai Lifesciences Holdings has reported EBT over the past 6 years, most recently at -$63.0 million for Q4 2025.

  • Quarterly results put EBT at -$63.0 million for Q4 2025, down 36.76% from a year ago — trailing twelve months through Dec 2025 was -$235.0 million (up 10.14% YoY), and the annual figure for FY2025 was -$235.0 million, up 10.14%.
  • EBT for Q4 2025 was -$63.0 million at Maravai Lifesciences Holdings, down from -$45.1 million in the prior quarter.
  • Over the last five years, EBT for MRVI hit a ceiling of $656.2 million in Q4 2023 and a floor of -$172.1 million in Q3 2024.
  • Median EBT over the past 5 years was -$8.9 million (2023), compared with a mean of $60.2 million.
  • Biggest five-year swings in EBT: surged 21448.45% in 2021 and later tumbled 737.15% in 2024.
  • Maravai Lifesciences Holdings' EBT stood at $144.7 million in 2021, then plummeted by 33.74% to $95.9 million in 2022, then skyrocketed by 584.41% to $656.2 million in 2023, then crashed by 107.02% to -$46.1 million in 2024, then crashed by 36.76% to -$63.0 million in 2025.
  • The last three reported values for EBT were -$63.0 million (Q4 2025), -$45.1 million (Q3 2025), and -$74.1 million (Q2 2025) per Business Quant data.